Back

Longitudinal Profiling of CD4⁺ T Cell Responses Following de novo Yellow Fever Vaccination

Gojak, D.; Kuznetsova, M.; Van Deuren, V.; Alcedo, S.; Willems, E.; Besbassi, H.; Bond, R.; Bartholomeus, E.; Marien, J.; Arien, K. K.; Meysman, P.; Soentjes, P.; Ha, M. K.; Ogunjimi, B.

2026-02-28 immunology
10.64898/2026.02.26.708120 bioRxiv
Show abstract

The yellow fever 17D vaccine is one of the most successful live-attenuated viral vaccines, yet the cellular mechanisms underlying its long-term protection remain not fully understood. This study provides a longitudinal analysis of the human CD4+ T cell and IgG response following de novo yellow fever vaccination by focusing. Peripheral blood mononuclear cells (PBMCs) from 49 vaccinated individuals were stimulated with yellow fever (YF) and control peptide pools across four timepoints: pre-vaccination/baseline (D1), day 22 (D22), day 43 (D43), and one year (D365) post-vaccination. Activation-induced marker (AIM) assays confirmed robust activation of CD4+ T cells following yellow fever peptide stimulation, peaking at day 22 post-vaccination and subsequently declining. T-cell receptor (TCR{beta}) sequencing of AIM-sorted CD4+ T cells showed a transient increase in clonal diversity at D22, consistent with broad epitope targeting and early polyclonal expansion. This was followed by repertoire contraction, which could indicate the persistence of a limited set of dominant clonotypes responsible for immune memory formation. TCR repertoires remained largely private over time, indicating a mostly individualized immune response. Next, serological analyses revealed a robust and highly yellow fever virus (YFV)-specific IgG response. Antibody levels peaked within the D22-D43 window and remained elevated at one year post-vaccination. Cross-reactivity toward other flaviviruses was limited, suggesting an antigen-specific humoral response. Together, these findings characterize the longitudinal dynamics of the CD4+ T cell and IgG response following de novo yellow fever vaccination and provide insights into the mechanisms contributing to durable antiviral immunity.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 4%
22.1%
2
Cell Reports
1338 papers in training set
Top 8%
6.2%
3
npj Vaccines
62 papers in training set
Top 0.1%
4.8%
4
mBio
750 papers in training set
Top 4%
4.2%
5
Cell Reports Medicine
140 papers in training set
Top 1%
3.9%
6
Science Translational Medicine
111 papers in training set
Top 0.7%
3.9%
7
The Lancet Infectious Diseases
71 papers in training set
Top 0.8%
3.5%
8
Nature Immunology
71 papers in training set
Top 0.7%
3.2%
50% of probability mass above
9
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 23%
3.0%
10
Frontiers in Immunology
586 papers in training set
Top 3%
2.5%
11
Immunity
58 papers in training set
Top 2%
2.5%
12
Cell Systems
167 papers in training set
Top 6%
2.0%
13
Science Advances
1098 papers in training set
Top 13%
2.0%
14
eLife
5422 papers in training set
Top 39%
1.8%
15
Molecular Therapy
71 papers in training set
Top 1%
1.8%
16
Journal of Virology
456 papers in training set
Top 2%
1.8%
17
PLOS Pathogens
721 papers in training set
Top 5%
1.8%
18
Cell Discovery
54 papers in training set
Top 3%
1.7%
19
Cell
370 papers in training set
Top 12%
1.7%
20
Cell Host & Microbe
113 papers in training set
Top 3%
1.6%
21
Science Immunology
81 papers in training set
Top 1%
1.3%
22
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.3%
23
Nature Microbiology
133 papers in training set
Top 3%
1.3%
24
eBioMedicine
130 papers in training set
Top 2%
1.2%
25
PLOS Biology
408 papers in training set
Top 14%
1.2%
26
Science
429 papers in training set
Top 17%
1.1%
27
iScience
1063 papers in training set
Top 30%
0.8%
28
Nature Medicine
117 papers in training set
Top 5%
0.8%
29
JCI Insight
241 papers in training set
Top 8%
0.7%
30
Nature
575 papers in training set
Top 16%
0.7%